NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
WASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research,...
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports...
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman,...
Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, Gamma-Delta T cell Engagers, CAR-Gamma-Delta T Cells...
SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today announced the expansion of...
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -...
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -...
WATERTOWN, Mass. and DRESDEN, Germany, June 2, 2026 /PRNewswire/ -- AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T...
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company...
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing...
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers,...
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation...
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation...
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a...
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential...
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed...